Cvs Health Corporation Reports Third Quarter 2026 Results and Raises Full-year 2026 Guidance

CVS Health posts strong Q3 results, raises 2026 earnings and cash flow guidance.

What the company is saying

CVS Health reports a 5.4% year-over-year increase in third quarter revenues to $108.4 billion, highlighting a swing from a prior-year GAAP diluted EPS loss of $3.13 to a profit of $1.68. The company attributes this improvement to the absence of a $5.7 billion goodwill impairment charge and stronger adjusted operating income, especially in the Health Care Benefits segment. Adjusted EPS rose to $2.09 from $1.60, with management citing margin recovery and improved performance in Government business as key drivers. Chairman and CEO David Joyner frames the results as evidence of successful execution on strategy and continued operational momentum. The company raises its full-year 2026 guidance for GAAP diluted EPS to at least $6.98, adjusted EPS to at least $8.20, and cash flow from operations to at least $15.5 billion, reflecting confidence in ongoing segment performance but also notes caution due to elevated cost trends and macroeconomic headwinds. Operational highlights include Aetna's strong Medicare Advantage ratings and Health100's accreditation, positioning CVS as a leader in consumer health solutions.

What the data suggests

The disclosed figures confirm a material improvement in CVS Health’s financial trajectory. Third quarter revenues reached $108.4 billion, up $5.5 billion year-over-year, with operating income turning positive at $3.6 billion versus a $3.2 billion loss in the prior year. Net income for the quarter was $2.2 billion, reversing a $4.0 billion loss. Adjusted EPS increased to $2.09 from $1.60, and year-to-date cash flow from operations totaled $15.3 billion. Segment data shows Health Care Benefits adjusted operating income nearly tripled to $912 million, with the medical benefit ratio improving to 91.3%. The Health Services segment delivered $54.0 billion in revenue and $2.1 billion in adjusted operating income, while Pharmacy & Consumer Wellness saw adjusted operating income rise to $1.6 billion despite a 2% revenue decline. The company’s raised full-year 2026 guidance is grounded in these realised gains, with no evidence of overstatement. Qualitative claims about Medicare Advantage ratings and competitive positioning are not fully quantified but do not detract from the robust financial disclosures.

Analysis

The announcement's tone is positive but proportionate to the substantial realised financial and operational progress disclosed. The majority of key claims are realised and supported by detailed numerical data, including revenue, operating income, net income, EPS, and cash flow from operations, all showing clear year-over-year improvement. Forward-looking statements are limited to raised full-year 2026 guidance, which is near-term and grounded in the strong results already achieved through Q3. There is no evidence of narrative inflation or exaggerated claims; qualitative statements about Medicare Advantage ratings and competitive positioning are not central to the investment case and do not distort the overall signal. No large capital outlay is disclosed without immediate earnings impact, and the guidance increases are justified by current performance. The data supports a strong positive signal with no material gap between narrative and evidence.

Risk flags

• ●Elevated healthcare cost trends remain a risk, as the company explicitly maintains a cautious outlook for the remainder of 2026 despite raising guidance. If cost inflation accelerates, margin recovery could stall.
• ●Macro headwinds are cited as a potential threat to continued performance. Economic downturns, regulatory changes, or shifts in consumer behavior could impact revenue growth and profitability.
• ●The improvement in GAAP EPS is partly due to the absence of a one-time $5.7 billion goodwill impairment charge in 2025. Future results could be affected if new impairments or other non-recurring charges arise.
• ●Segment-specific risks persist: the Pharmacy & Consumer Wellness segment experienced a revenue decline due to regulatory price reductions and reimbursement pressure, which could continue to weigh on top-line growth.
• ●Qualitative claims about Medicare Advantage ratings and competitive positioning are not fully substantiated with detailed data, introducing some uncertainty about the sustainability of these competitive advantages.

Bottom line

CVS Health’s Q3 results show a clear turnaround, with strong revenue growth, a return to operating and net profitability, and robust cash flow generation. The company’s decision to raise full-year 2026 guidance for both earnings and cash flow is well-supported by realised segment gains, especially in Health Care Benefits and Health Services. While management’s tone is confident, they acknowledge ongoing risks from healthcare cost inflation and macroeconomic factors. The improvement in GAAP earnings is partly due to the absence of a prior-year impairment, so underlying performance trends are best measured by adjusted metrics, which also show solid growth. Investors should focus on the company’s ability to sustain margin recovery and manage cost pressures in coming quarters. The most important takeaway is that CVS Health is delivering on its operational and financial targets, with near-term guidance upgrades underpinned by concrete results.

Announcement summary

(NYSE:CVS) CVS Health Corporation reported third quarter total revenues of $108.4 billion, representing a 5.4% increase year-over-year. Third quarter GAAP diluted earnings per share (EPS) were $1.68, compared to a loss per share of $3.13 in the prior year, reflecting the absence of a $5.7 billion goodwill impairment charge recorded in the third quarter of 2025. Adjusted EPS for the quarter was $2.09, up from $1.60 in the prior year, primarily due to improved adjusted operating income in the Health Care Benefits segment. Year-to-date cash flow from operations was $15.3 billion. The company raised its full-year 2026 guidance, increasing GAAP diluted EPS guidance to at least $6.98 from a range of $6.84 to $7.04, and Adjusted EPS guidance to at least $8.20 from a range of $7.90 to $8.10. Cash flow from operations guidance was also raised to at least $15.5 billion from at least $11.5 billion. For the three months ended September 30, 2026, total revenues were $108,399 million, up from $102,871 million in the prior year, with a change of $5,528 million. Operating income for the quarter was $3,566 million, compared to an operating loss of $3,207 million in the prior year. Adjusted operating income was $4,194 million, up from $3,459 million. Net income for the quarter was $2,171 million, compared to a net loss of $3,990 million in the prior year. For the nine months ended September 30, 2026, total revenues were $314,921 million, up from $296,374 million, with a change of $18,547 million. Diluted EPS for the nine months was $6.29, compared to a loss of $0.93 in the prior year. Adjusted EPS for the nine months was $7.24, up from $5.66. In the Health Care Benefits segment, third quarter total revenues were $36,855 million, up from $35,993 million, with adjusted operating income of $912 million, up from $314 million. The medical benefit ratio (MBR) for the quarter was 91.3%, down from 92.8%. Medical membership as of September 30, 2026 was 26.1 million. Prior years' health care costs payable estimates developed favorably by $1.3 billion during the nine months ended September 30, 2026. Days claims payable were 41.9 days as of September 30, 2026. In the Health Services segment, third quarter total revenues were $53,964 million, up from $49,266 million, with adjusted operating income of $2,106 million, up from $2,050 million. Pharmacy claims processed in the quarter were 481.7 million, up from 475.6 million. In the Pharmacy & Consumer Wellness segment, third quarter total revenues were $35,498 million, down from $36,214 million, with adjusted operating income of $1,635 million, up from $1,478 million. Prescriptions filled in the quarter were 470.0 million, up from 461.4 million. As of September 30, 2026, CVS Health had approximately 9,000 retail pharmacy locations and more than 1,000 walk-in and primary care medical clinics. The company serves approximately 87 million pharmacy benefits plan members and an estimated 37 million people through health insurance products and related services. David Joyner is the Chairman and CEO of CVS Health. The company highlighted that more than 69 percent of Aetna Medicare Advantage members are in 2027 plans rated 4 stars or higher by the Centers for Medicare & Medicaid Services, positioning Aetna second among large, publicly traded Medicare Advantage organizations in the Star Ratings program. CVS Pharmacy offers all FDA-approved GLP-1s and provides integrated weight management offerings. Health100, a CVS Health subsidiary, earned the CARIN Code of Conduct for Consumer-Facing Applications Accreditation from DirectTrust for the Health100 mobile app.

Disagree with this article?